Scandinavian ChemoTech AB announced that the company has received approval from the European Patent Office. The final injunction for this patent application was announced in a press release on the 3d of February 2021. The examiner announces that the approval will be published 7th of July 2021. The patent covers a specially developed electrode as well as unique dynamic properties, which already exist in the TSE platform, intended to treat tumours without damaging important parts of organs and tissues such as nerve pathways and blood vessels. This is of utmost importance in the treatment of, among other things, the spine and prostate. This innovation provides improved pain control when using the Company's DEEPC(TM) (Dynamic Electro Enhanced Pain Control) device for IQwave(TM), for the delivery of electrical pulses to the desired body part.